What It Is
Cartalax is a synthetic tripeptide made from three amino acids — alanine, glutamic acid, and aspartic acid — commonly written as Ala-Glu-Asp or AED. PubChem lists it as alanyl-glutamyl-aspartic acid, with a molecular formula of C12H19N3O8 and a molecular weight of about 333 g/mol.[1] Like other peptide bioregulators, it is discussed mainly in connection with cartilage, connective tissue, and cellular-aging biology rather than as an approved therapeutic.
How It Works
Cartalax's proposed mechanism centers on chondrocytes, the cells that produce and maintain cartilage's extracellular matrix. In a 2023 laboratory study, AED at a mid-range concentration (200 ng/mL) increased the number of chondrocytes cultured from both young and old rats.[2] Separately, short-peptide research literature proposes that sequences like AED may influence genes tied to cellular aging — including IGF1 and NF-kB in cultured stem cells — and pathways involving senescence markers such as p53, p16, and p21.[4] These are cell-culture signals suggesting biological plausibility, not evidence that Cartalax changes cartilage biology inside a living joint, where mechanical load, limited blood supply, and the surrounding joint environment all matter in ways a petri dish cannot replicate.
What the Research Shows
The most directly relevant Cartalax studies are the 2023 rat chondrocyte culture experiment and a related paper on peptide regulation of chondrogenic stem-cell differentiation — both laboratory work, not clinical research.[2][3] No FDA-approved indication, registered clinical-trial program, or peer-reviewed human study evaluating Cartalax for osteoarthritis, joint pain, or cartilage regeneration was identified. This matters because osteoarthritis already has well-established, guideline-based treatment options, from exercise and weight management to specific medications and injections, none of which have been compared against Cartalax in a controlled human study.[15] Claims that it “regenerates cartilage” or “reverses aging” in people are not supported by current published evidence.
Safety & Side Effects
There is no FDA-approved label for Cartalax and therefore no official adverse-reaction, warning, or contraindication data.[6][7] Concerns that generally apply to unapproved or poorly characterized peptides are relevant background but not Cartalax-specific findings:
- Inconsistent potency and manufacturing impurities
- Contamination risk in unregulated products
- Unpredictable immune reactions
People who are pregnant or breastfeeding, have autoimmune disease or a cancer history, or take complex medication regimens should recognize that essentially no safety data exist for this compound in those populations.[9]
Regulatory Status
No FDA-approved Cartalax product, prescribing information, or approved dosage was found in FDA drug-approval or labeling databases, nor in the European Medicines Agency's authorized-medicines listings.[6][7][18] Cartalax remains, at this point, a research compound — not an approved medicine for cartilage repair, osteoarthritis, or any other condition in the United States or European Union.